Kiniksa Pharmaceuticals, Ltd.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.2Mgeneral payments (2019-2025)
$34Kresearch payments (2019-2025)
9,603clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Robert Biederman | Charleston, SC | Cardiovascular Disease | $82,782.23 |
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $67,213.92 |
| Norman Lepor | Beverly Hills, CA | $48,197.32 | |
| Petros Efthimiou | New York, NY | Rheumatology | $39,300.64 |
| Antonio Abbate | Charlottesville, VA | Cardiovascular Disease | $37,765.58 |
| Dipan Shah | Houston, TX | Cardiovascular Disease | $36,776.78 |
| Ajit Raisinghani | San Diego, CA | Cardiovascular Disease | $31,941.42 |
| Deepak Talreja | Virginia Beach, VA | Interventional Cardiology | $30,124.18 |
| John Isaac | Houston, TX | Interventional Cardiology | $27,336.26 |
| Timothy Henry | Cincinnati, OH | Interventional Cardiology | $25,707.39 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.